Zero Deaths vs. Zero Trust: How England Solved Cervical Cancer While the US Chases Litigation
(SeaPRwire) –
By: Sylvia Brooks
England just recorded a historic public health victory. Between 2020 and 2024, not one woman aged twenty to twenty-four died of cervical cancer. This is a first since records began. The expected number was roughly twenty-three. This finding comes from a landmark Lancet study. Professors Sasieni and Falcaro authored the report. They spent two decades proving the causal chain. HPV causes the cancer. Vaccination stops the infection. Vaccination stops the dying. The success rate is staggering. There was a one hundred percent reduction in mortality. This is thanks to school vaccination programs. Nearly ninety percent of Gen Z women received the vaccine. The underlying risk has been driven so low that zero is now plausible. It is a triumph of state procurement.
The United States is failing to replicate this model. The vaccine is effective here. A US analysis found twenty-six fewer deaths than projected. Yet the national uptake is stalling. Only sixty-one percent of adolescents completed the series. This lags behind the meningococcal vaccine. That rate sits at eighty-eight percent. The Tdap rate is eighty-nine percent. HPV initiation has stalled for three years. The blame lies with policy leadership. Robert F. Kennedy Jr. is now in charge. He has refused to affirm the vaccine’s safety. He previously called Gardasil dangerous and defective. He fired the entire CDC vaccine advisory committee. He replaced them with skeptics. He forced out the FDA’s top regulator. The government’s goal of eighty percent coverage is now impossible.
The market dynamics are distorted by litigation. Merck’s Gardasil generated over eight billion dollars in sales in 2023. It now faces its first US jury trial. The claims allege wrongful marketing. Kennedy has financially benefited from this. He received referral fees from plaintiffs’ firms. This creates a massive conflict of interest. He is tasked with public health. He is profiting from attacking the primary tool. The rhetoric is having an impact. Uptake is depressed in conservative-leaning states. The WHO estimates six hundred twenty thousand cancer cases in women and seventy thousand in men in 2019. These span cervical, anal, and other cancers. Cervical cancer alone killed three hundred fifty thousand in 2022. Global coverage is abysmal. Only twenty percent of girls get a first dose. Just fifteen percent complete the series. The US is contributing to this failure. We are ignoring the evidence. We are prioritizing legal battles over clinical prevention.
The future landscape looks bleak for US patients. The CDC estimates thirty-nine thousand HPV-caused cancers annually in the US. Nearly all are preventable with the nine-valent Gardasil vaccine. But prevention requires access and trust. The current administration is undermining both. They are investigating the childhood schedule. They are not promoting the HPV shot. As vaccinated generations in England age, mortality will drop further. In the US, we will see a plateau. The gap between the two nations will grow. The clinical pipeline remains open. The political will has been severed. We are trading saved lives for political points.
Author bio: Sylvia Brooks, a veteran analyst of healthcare procurement policy and pharmaceutical pricing mechanisms.